Pernix Therapeutics (PTX) Reports Q2 Loss of $0.47/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
UPDATE: Brean Capital Downgrades Pernix Therapeutics (PTX) to Hold
August 12, 2016 7:05 AM EDT(Updated - August 12, 2016 10:35 AM EDT)
Brean Capital downgraded Pernix Therapeutics (NASDAQ: PTX) from Buy to Hold and removed its price target. The change followed the release of Q2 results. Analyst Difei Yang said the pathway to sustainable revenue growth and profitability is... More
